Clinical Trial: Mesalazine for Irritable Bowel Syndrome with Diarrhea (IBS-D), United Kingdom

The Nottingham University Hospitals Trust, King’s Mill Hospital Mansfield, Derby Royal Hospital and Wythenshawe Hospital Manchester are looking for men and women age 18-75 with Rome III criteria diarrhea-predominant IBS to participate in a clinical trial of the medication mesalazine for the treatment of IBS. Other eligibility requirements or exclusions may apply.  Mesalazine is a common, established treatment for inflammatory bowel disease (IBD). Because of recent research showing that chronic, low-level gut inflammation may be a factor in irritable bowel syndrome, the researchers hypothesize that mesalazine may be an effective treatment for IBS as well.

The study involves 4 hospital visits of 1-2 hours each over the course of 14 weeks. Participants will receive either a placebo or mesalazine in a double-blind protocol, meaning neither the volunteers nor the doctor or nurse will be aware of whether specific individuals are given mesalazine or a placebo.

Volunteers who complete the study will be paid 150 pounds as compensation for expenses or time off from employment.

For further information, contact Dr Ching Lam (Clinical Research Fellow) at or 01159249924 ext 7061.

IBS Impact has summarized this information from a posting on the website of the IBS Network, the national charity for irritable bowel syndrome in the U.K. and this study’s current listing at, a worldwide database that is administered by the United States National Institutes of Health.


  1. Anna

    Hi I am wondering if you got any outcome from the study as I suffer from post infection ibs. Would love to find a treatment which would help me get my normal life back.

    • Thank you for visiting the blog. This study listing came to our attention more than a year ago. From publicly available information, it appears to have been completed, however, results specific to this trial have not yet been published. Based on the published abstracts of previous clinical trials from the University of Nottingham, as well as other research facilities in other countries, mesalazine appears promising for some people with IBS-D, but the studies are small and preliminary. Presumably, additional trials will continue in various places, but it will likely be quite some time before cumulative results are considered definitive enough for regulatory approval to be sought and this specific medication to come available for prescription in any country. Good luck to you.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s